Amyloid-β PET recently qualified for the European regulatory agency (European Medicines Agency, or EMA) as a biomarker for population enrichment of clinical trials with prodromal and mild-moderate AD subjects (EMA/CHMP/SAWP/893622/2011 and EMA/CHMP/SAWP/892998/2011).
![[This page as RDF]](http://data.gesis.org/somesci/static/rdf-icon.gif){kind=icon}